Stock Price of Diplomat Pharmacy, Inc. (DPLO) Increases 15.61%

Stock price performance of Diplomat Pharmacy, Inc. is analyzed for various periods using several stock trading signals. In this case, The stock price has rallied 4.31% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -55.78% . Looking at the past 52 week period, the stock price is down -42.33% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Diplomat Pharmacy, Inc. has a negative value of -54.02 compared to overall market performance. Company shares have received an average consensus rating of Hold for the current week The stock has recorded a 20-day Moving Average of 0.46% and the 50-Day Moving Average is 3.43%.The 200 Day SMA reached 50.47%

Diplomat Pharmacy, Inc. is having a Relative Strength Index of 64.22 which indicates the stock is not yet over sold or over bought based on the technical indicators. Diplomat Pharmacy, Inc. (NYSE:DPLO) has climbed 15.61% in the past week and advanced 15.34% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 15.47% and the outperformance has advanced to 14.32% for the last 4 weeks period.

Company has reported several Insider transactions to the SEC, on Sep 16, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 20,000 shares at 30.12 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at 33.60 per share price.On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at 35.08 per share price.

Diplomat Pharmacy Inc Last issued its quarterly earnings results on Nov 2, 2016. The company reported $0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.24. The company had revenue of $1181.00 million for the quarter, compared to analysts expectations of $1258.11 million. The companys revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Diplomat Pharmacy Inc was Downgraded by Credit Suisse to Underperform on Nov 23, 2016.

Diplomat Pharmacy, Inc. (NYSE:DPLO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.27 points or 1.74% at $15.26 with 2,225,114 shares getting traded. Post opening the session at $15.68, the shares hit an intraday low of $14.9675 and an intraday high of $15.75 and the price was in this range throughout the day. The company has a market cap of $1,018 million and the number of outstanding shares has been calculated to be 66,730,998 shares. The 52-week high of Diplomat Pharmacy, Inc. (NYSE:DPLO) is $38.94 and the 52-week low is $12.25.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.


Share this post

Leave a Reply